Advances in multiple myeloma: key updates from the ASH 2025 meeting
Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.
This study investigated the occurrence of progressive multifocal leukoencephalopathy (PML) in patients with multiple myeloma receiving bispecific antibody (BsAb) therapy.
It is unknown whether use of BsAbs increases risk of PML in multiple‑myeloma patients, an important safety question for clinicians and patients.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Multiple Myeloma Clinical Trials & Emerging Therapies
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy